FCM
SLDB icon

Flinton Capital Management’s Solid Biosciences SLDB Stock Holding History

Flinton Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-118
Closed -$47K – 889
2018
Q4 		$47K Buy
+118
New +$55.5K ﹤0.01% 801

Other funds holding SLDB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Flinton Capital Management's SLDB Position: Q1 2019 in Review

Flinton Capital Management sold out of Solid Biosciences (SLDB) in Q1 2019, closing a stake of 118 shares — an estimated $47K sold.

Flinton Capital Management first reported a position in SLDB in Q4 2018 and held it in 1 quarter. The position peaked at $47K in Q4 2018. 74 funds tracked by Wall St. Rank hold SLDB as of Q1 2019.

  • Flinton Capital Management reported no remaining Solid Biosciences position as of Q1 2019 after selling out during the quarter.
  • Flinton Capital Management sold 118 Solid Biosciences shares in Q1 2019, an estimated $47K.
  • Flinton Capital Management first reported a position in Solid Biosciences in Q4 2018 and held it in 1 quarter.
  • Flinton Capital Management's Solid Biosciences position peaked at $47K in Q4 2018.
  • 74 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2019.

Based on Flinton Capital Management's 13F filing for Q1 2019, filed 13 May 2019.